FDA recommends thyroid monitoring in babies and young children who receive injections of iodine-containing contrast media for medical imaging

If your email program has trouble displaying this email, view as a webpage. Drug Safety Communication Based on our recent review of published studies, the U.S. Food and Drug Administration (FDA) is recommending that newborns and children through 3 years old have follow-up thyroid monitoring within 3 weeks after receiving injections of contrast media containing iodine, also called "contrast dye," for X-rays and other medical imaging procedures.  Our review showed that underactive thyroid or a temporary decrease in thyroid hormone levels were uncommon.  However, the conditions should be identified and treated early when needed to prevent potential future complications.  Newborns, particularly those born premature, and children in their first 3 years with underlying conditions such as heart issues may be at higher risk for problems of the thyroid, a gland in the neck that releases hormones that help control many of the body's functions.  For more information, read the complete Drug Safety Communication.

Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA